Tiziana enters a collaboration agreement with fhi clinical to conduct a phase 2 clinical trial for treating hospitalized severe covid-19 patients with intranasal foralumab, a fully human anti-cd3 monoclonal antibody

New york and london, june 23, 2021 (globe newswire) -- tiziana life sciences plc (nasdaq: tlsa, lse: tils), ("tiziana" or the "company"), a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces that it has signed an agreement with fhi clinical, a global clinical contract research organization (cro), to conduct a phase 2 proof-of-concept study in brazil to evaluate the safety, tolerability and efficacy of intranasal foralumab in hospitalized patients with severe coronavirus disease 2019 (covid-19) and pulmonary inflammation.
TLSA Ratings Summary
TLSA Quant Ranking